Given the high frequency of BRAF mutations, targeted BRAF inhibitors (BRAFis), such as vemurafenib and dabrafenib, were developed for advanced melanoma therapy; however, patients treated with a BRAFi eventually experience drug resistance [11]. This evidence concerns the gene BRAF and melanoma.